EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Sequential EGFR T790M , MET c. 3010C >G‐Associated Exon 14 Alteration, and RET ‐ CCDC6 Fusion in EGFR ‐Mutant NSCLC : A Case Report

Yan Zhu iD, Chan Wang, Nan-Lin Hu iD, Dan-He Wang, Shi-Kai Wu

Thoracic Cancer · 2026-07 · 17 (14)

DOI: 10.1111/1759-7714.70322 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Thoracic Cancer, online erschienen am 26.07.2026. Verfasst von Yan Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Proto-Oncogene Proteins c-met, Proto-Oncogene Proteins c-ret. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR‐mutant non–small‐cell lung cancer (NSCLC) is heterogeneous, and serial re‐biopsy may uncover actionable mechanisms. We report a 55‐year‐old man with stage IVB lung adenocarcinoma harboring EGFR L858R and TP53 R282W. First‐line icotinib produced a partial response (PR) with progression‐free survival (PFS) of 7 months. Rebiopsy at progression identified acquired EGFR T790M together with a MET c.3010C>G exon 14‐related alteration. Almonertinib induced a second PR lasting 7 months. After renewed progression, almonertinib plus savolitinib achieved another PR for 8 months, supporting MET‐dependent bypass resistance. Biopsy of a newly progressive iliac metastasis then showed emergence of RET‐CCDC6 fusion, whereas T790M and the MET alteration were no longer detected. Because selective RET inhibition was initially unaffordable, the patient received pemetrexed‐carboplatin plus continued almonertinib, followed by selpercatinib plus almonertinib. Local radiotherapy to oligoprogressive bone and lung lesions prolonged benefit from systemic therapy. At the latest follow‐up in January 2026, the patient remained alive nearly 50 months after diagnosis. This case illustrates clonal evolution under treatment pressure and highlights three practical lessons: repeat molecular testing at each clinically meaningful progression, matched combination targeted therapy for actionable bypass alterations, and local ablative radiotherapy for oligoprogression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsProto-Oncogene Proteins c-metProto-Oncogene Proteins c-retHumansMaleMiddle AgedErbB ReceptorsExonsMutation

Stichwörter der Autor:innen

EGFR mutationMET exon 14 alterationRET fusionacquired resistancenon–small‐cell lung cancer

Substanzen

ErbB ReceptorsProto-Oncogene Proteins c-metEGFR protein, humanProto-Oncogene Proteins c-retRET protein, humanMET protein, human

Autor:innen und Institutionen

  • Department of Oncology, Peking University First Hospital, Beijing, China.

ORCID-Profile: Yan Zhu, Nan-Lin Hu

Zitieren

APA

Zhu, Y., Wang, C., Hu, N. L., Wang, D. H., & Wu, S. K. (2026). Sequential EGFR T790M , MET c. 3010C >G‐Associated Exon 14 Alteration, and RET ‐ CCDC6 Fusion in EGFR ‐Mutant NSCLC : A Case Report. Thoracic Cancer, 17(14). https://doi.org/10.1111/1759-7714.70322

Vancouver

Zhu Y, Wang C, Hu NL, Wang DH, Wu SK. Sequential EGFR T790M , MET c. 3010C >G‐Associated Exon 14 Alteration, and RET ‐ CCDC6 Fusion in EGFR ‐Mutant NSCLC : A Case Report. Thoracic Cancer. 2026;17(14). doi:10.1111/1759-7714.70322

BibTeX
@article{Zhu2026,
  author = {Zhu, Yan and Wang, Chan and Hu, Nan-Lin and Wang, Dan-He and Wu, Shi-Kai},
  title = {Sequential EGFR T790M , MET c. 3010C >G‐Associated Exon 14 Alteration, and RET ‐ CCDC6 Fusion in EGFR ‐Mutant NSCLC : A Case Report},
  journal = {Thoracic Cancer},
  year = {2026},
  volume = {17},
  number = {14},
  doi = {10.1111/1759-7714.70322}
}
Kostenlos starten →